Biotech · Private company
TILT Biotherapeutics Ltd.
Track this companyFree. Adds TILT Biotherapeutics Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials33 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- pegylated liposomal doxorubicinPhase 2 · Platinum-refractory Ovarian CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 2 · Platinum-refractory Ovarian CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TILT-123Phase 2 · Platinum-refractory Ovarian CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- AvelumabPhase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- KEYTRUDA®Phase 1 · Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- TILT-123Phase 1 · Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- TILT-123Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 23, 2024ClinicalTrials.gov NCT06125197 · fetched Nov 12, 2026
- Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1PHASE1 · ACTIVE_NOT_RECRUITING · started Mar 8, 2023ClinicalTrials.gov NCT05222932 · fetched Nov 12, 2026
- Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 17, 2022ClinicalTrials.gov NCT05271318 · fetched Nov 12, 2026